Trial reportEuropean journal of nuclear medicine and molecular imaging2012
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Trial report in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02062099 (PET Imaging of the Translocator Proteine Ligands), which is not on this map. Cited by 116 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)
Who cites it
116 citing papers in PubMed, 3 syntheses or guidelines pooled it, 249 citations in OpenAlex.
- Amyloid-β PET in Alzheimer's disease: A systematic review and Bayesian meta-analysis.Brain and behavior · 2023Pooled it
- Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.BMC geriatrics · 2016Pooled it
- Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2016Pooled it
- A Fully Automatic Technique for Precise Localization and Quantification of Amyloid-β PET Scans.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Trial
- Cognitive changes of older adults with an equivocal amyloid load.Journal of neurology · 2019Trial
- β-Amyloid accumulation in the human brain after one night of sleep deprivation.Proceedings of the National Academy of Sciences of the United States of America · 2018Trial
- Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings.European journal of nuclear medicine and molecular imaging · 2015Trial
- Probabilistic Joint and Individual Variation Explained (ProJIVE) for Data Integration.Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America · 2026Article
- Regional cerebral hypometabolism and pathological heterogeneity in sporadic early onset alzheimer's disease: China Aging and Neurodegenerative Initiative (CANDI) study.European journal of nuclear medicine and molecular imaging · 2026Article
- Comparative Analysis of Deep Learning Techniques in Alzheimer's Disease Diagnosis: Trends, Challenges, and Future Directions.MethodsX · 2026Review
- PROTAC-Mediated Degradation of mHTT Aggregates Attenuates Neurotoxicity in Cellular and R6/2 Mouse Models of Huntington's Disease.Journal of the American Chemical Society · 2026Article
- Discovery of NIRF theranostic probes targeting amyloid-β and cholinesterases in Alzheimer's disease models.Nature communications · 2026Article
- MEMOIR-VLM-a multimodal vision-language model for Alzheimer's disease classification and question answering.Frontiers in computational neuroscience · 2026Article
- DG-DiT: Dual-Branch Gating Diffusion Transformer for Multi-Tracer and Multi-Scanner Brain PET Image Denoising.IEEE transactions on radiation and plasma medical sciences · 2025Article
- Selective vulnerability and resilience to Alzheimer's disease tauopathy as a function of genes and the connectome.Brain : a journal of neurology · 2025Article
- Potential Role of Lymphovenous Bypass in Mitigating Alzheimer's Disease Dementia.Archives of plastic surgery · 2025Article
- Deep-learning based multi-modal models for brain age, cognition and amyloid pathology prediction.Alzheimer's research & therapy · 2025Article
- Quantitative magnetic resonance imaging in Alzheimer's disease: a narrative review.Quantitative imaging in medicine and surgery · 2025Review
- Multi-Modal Diagnosis of Alzheimer's Disease Using Interpretable Graph Convolutional Networks.IEEE transactions on medical imaging · 2025Article
- Interrater agreement and variability in visual reading of [18F] flutemetamol PET images.Annals of nuclear medicine · 2025Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePositron emission tomography (PET) imaging of brain amyloid load has been suggested as a core biomarker for Alzheimer's disease (AD). The aim of this study was to test the feasibility of using PET imaging with (18)F-AV-45 (florbetapir) in a routine clinical environment to differentiate between patients with mild to moderate AD and mild cognitive impairment (MCI) from normal healthy controls (HC).
methodsIn this study, 46 subjects (20 men and 26 women, mean age of 69.0 ± 7.6 years), including 13 with AD, 12 with MCI and 21 HC subjects, were enrolled from three academic memory clinics. PET images were acquired over a 10-min period 50 min after injection of florbetapir (mean ± SD of radioactivity injected, 259 ± 57 MBq). PET images were assessed visually by two individuals blinded to any clinical information and quantitatively via the standard uptake value ratio (SUVr) in the specific regions of interest, which were defined in relation to the cerebellum as the reference region.
resultsThe mean values of SUVr were higher in AD patients (median 1.20, Q1-Q3 1.16-1.30) than in HC subjects (median 1.05, Q1-Q3 1.04-1.08; p = 0.0001) in the overall cortex and all cortical regions (precuneus, anterior and posterior cingulate, and frontal median, temporal, parietal and occipital cortex). The MCI subjects also showed a higher uptake of florbetapir in the posterior cingulate cortex (median 1.06, Q1-Q3 0.97-1.28) compared with HC subjects (median 0.95, Q1-Q3 0.82-1.02; p = 0.03). Qualitative visual assessment of the PET scans showed a sensitivity of 84.6% (95% CI 0.55-0.98) and a specificity of 38.1% (95% CI 0.18-0.62) for discriminating AD patients from HC subjects; however, the quantitative assessment of the global cortex SUVr showed a sensitivity of 92.3% and specificity of 90.5% with a cut-off value of 1.122 (area under the curve 0.894).
conclusionThese preliminary results suggest that PET with florbetapir is a safe and suitable biomarker for AD that can be used routinely in a clinical environment. However, the low specificity of the visual PET scan assessment could be improved by the use of specific training and automatic or semiautomatic quantification tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.